Systematically optimized topical delivery system for Loperamide hydrochloride: Formulation design, in vitro and in vivo biopharmaceutical evaluation

Jianhui Shu, Jingjing Zhao, Fang Guo*
Nanjing Sanhome Pharmaceutical CO., LTD. R&D Institute, Nanjing 211100, PR China

ABSTRACT
This study aimed to develop a suitable topical delivery system containing diethylene glycol monoethyl ether (DGME) for Loperamide hydrochloride (Lop). Two factors, three levels Central-Composite design were applied by generating a quadratic polynomial equation to form contour plots and response surface for prediction of responses as two selected independent variables with EtOH-DGME ratio and EtOH concentration. The response variables flux and skin retention were determined in in vitro hairless mouse skin model. The selected optimum formulation was evaluated for the skin transport characteristics by developing dermatokinetic analysis model and the results demonstrated DGME improved the delivery of Lop into skin deep layers, which was further confirmed by confocal laser scanning microscopy (CLSM) study. In vitro skin permeation was found to have triphasic correlation with plasma AUC in the in vivo pharmacokinetic study. The in vitro–in vivo correlation enabled the prediction of pharmacokinetic profile of Lop from in vitro permeation results. Therefore, the optimum formulation capable of enhancing Lop intracutaneous depot could be a candidate for topical delivery of Lop as analgesics.

© 2018 Production and hosting by Elsevier B.V. on behalf of Shenyang Pharmaceutical University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Analgesics of opiates act to produce antinociception not only through central mechanisms but also peripheral mechanisms by local actions. The peripheral analgesic effects in response to pain by local actions of opiates exhibit greater efficacy compared with nonsteroidal anti-inflammatory agents [1] and central analgesic. Loperamide hydrochloride is a hydrophobic compound which has been originally developed as a drug for the symptomatic relief of diarrhea associated with inflammatory bowel diseases for decades [2]. Meanwhile, Lop was also found to be a useful antihyperalgesic agent as a peripheral opiate agonist. Due to its high affinity and
selectivity for the μ subtype of the opioid receptor, Lop has received attention as an antihyperalgesic agent that reduces pain without addiction and any other central nervous system (CNS) side effects associated with other opiate administration such as morphine and heroin [1,3]. As a result, Lop could be a potent and fully efficacious hyperalgesic agent and the analgesic effects were due to topical actions at the opioid receptors in nociceptor associated with cutaneous nerves [1].

The noninvasive transdermal administration is a preferred method for pain relief. For topical drug delivery system, the main challenge was to penetrate across through the stratum corneum (SC) barrier and target the active drug into injury sites as much as possible without producing potential side effect to non-suffering organs. Thus effective drug concentration at the deeper layer (dermal/epidermal junction) must be achieved.

In topical application formulation studies, vehicle can affect both drug release and percutaneous absorption due to different solubility and different transport actions from the vehicle into the skin. Therefore, the interest of researchers has been particularly focused on the study of the effect of vehicle as possible permeation enhancers for topical drug transport [4,5].

For Lop, some of the ordinary effective topical preparations took N-methyl-2-pyrrolidone (NMP) as main vehicle in commercial products, whereas skin toxicity caused by NMP has been precluded because of adverse reactions, whereas skin toxicity caused by NMP has been reported at 32 °C. After Lop was dispersed in the formulation solution, 0.75% Klucel® MF 4000 (w/v) was added to the solution with continuous stirring until the solution was gelled.

For Lop, some of the ordinary effective topical preparations took N-methyl-2-pyrrolidone (NMP) as main vehicle in commercial products, whereas skin toxicity caused by NMP has been precluded because of adverse reactions, whereas skin toxicity caused by NMP has been reported at 32 °C. After Lop was dispersed in the formulation solution, 0.75% Klucel® MF 4000 (w/v) was added to the solution with continuous stirring until the solution was gelled.

2.3. HPLC analysis of Lop

The quantitative determination of Lop was performed with an HPLC system (HP1100, Agilent Technologies, Inc.) using acetonitrile-PBS (pH 3.0) (45:55, v/v) as mobile phase at a flow rate of 1.0 ml/min. The injection volume was 20 μl. A 250 mm × 4.6 mm C18 column (4.5 μm, Hypersil, USA) was used. The UV detector was set at 220 nm and the column was maintained at 35 °C.

2.4. In vitro skin permeation study

2.4.1. Skin membrane

Abdominal skin of male hairless mice was used for in vitro permeation studies. Male hairless mice (30–40 days old) weighing 18–20 g were obtained from Radiation Medicine Institute for Laboratory Animal Research, Chinese Academy of Medical Sciences (Tianjin, China). Mice were sacrificed humanely. Hair was carefully trimmed, then the abdominal skin was separated and subcutaneous fat was carefully removed. The skin membrane samples were stored at −20 °C. They were thawed to room temperature before used and equilibrated at 37 °C for 1h in receptor medium (PBS, pH 6.8) in Franz Diffusion Cell.

2.4.2. Skin permeation study

The excised skin mounted and clamped between the donor and receptor compartments of a Franz diffusion cell (1.77 cm²) assembly with the SC facing the donor compartment. 900 μl of the test formulation was applied to skin surface (35 μl/cm²). The receptor compartment (Volume = 16 ml) was filled with receptor medium which was stirred continuously at 37 ± 0.2 °C with a magnetic stirrer at 500 rpm. At each predetermined time intervals (1, 2, 4, 6, 8, 9, 10, 12 and 24 h), a sample was withdrawn from the receptor medium.

2.4.3. Skin retention determination

At the end of each time interval (1, 2, 4, 6, 8, 9, 10, 12 and 24 h), the drug deposited within the skin was determined. The skin surface was wiped with cotton ball soaked with 50% ethanol. The tape-stripping method (average 10 strips) was used to remove the SC layer. The remaining skin (epidermis/dermis) was weighed, cut into small pieces and homogenized with 0.5 ml of methanol. The extraction solution was then

2. Materials and methods

2.1. Materials

Lop was purchased from Sanyou chemical company (Changzhou, China). NMP, DGME and EtOH were provided by Yuanli chemical company (Tianjin, China). Rodamine 6G was purchased from Sigma Chemical Co. (St.Louis, USA). Acetonitrile and methanol were obtained from J.T. Baker (USA) of HPLC grade. All other reagents were readily from various commercial sources of analytical grade.

2.2. Preparation of gel formulations

The formulation solution with 5% (w/v) Lop was made with vehicle mixture by agitating on an environmental shaker at 32 °C. After Lop was dispersed in the formulation solution, 0.75% Klucel® MF 4000 (w/v) was added to the solution with continuous stirring until the solution was gelled.

2.3. HPLC analysis of Lop

The quantitative determination of Lop was performed with an HPLC system (HP1100, Agilent Technologies, Inc.) using acetonitrile-PBS (pH 3.0) (45:55, v/v) as mobile phase at a flow rate of 1.0 ml/min. The injection volume was 20 μl. A 250 mm × 4.6 mm C18 column (4.5 μm, Hypersil, USA) was used. The UV detector was set at 220 nm and the column was maintained at 35 °C.

2.4. In vitro skin permeation study

2.4.1. Skin membrane

Abdominal skin of male hairless mice was used for in vitro permeation studies. Male hairless mice (30–40 days old) weighing 18–20 g were obtained from Radiation Medicine Institute for Laboratory Animal Research, Chinese Academy of Medical Sciences (Tianjin, China). Mice were sacrificed humanely. Hair was carefully trimmed, then the abdominal skin was separated and subcutaneous fat was carefully removed. The skin membrane samples were stored at −20 °C. They were thawed to room temperature before used and equilibrated at 37 °C for 1h in receptor medium (PBS, pH 6.8) in Franz Diffusion Cell.

2.4.2. Skin permeation study

The excised skin mounted and clamped between the donor and receptor compartments of a Franz diffusion cell (1.77 cm²) assembly with the SC facing the donor compartment. 900 μl of the test formulation was applied to skin surface (35 μl/cm²). The receptor compartment (Volume = 16 ml) was filled with receptor medium which was stirred continuously at 37 ± 0.2 °C with a magnetic stirrer at 500 rpm. At each predetermined time intervals (1, 2, 4, 6, 8, 9, 10, 12 and 24 h), a sample was withdrawn from the receptor medium.

2.4.3. Skin retention determination

At the end of each time interval (1, 2, 4, 6, 8, 9, 10, 12 and 24 h), the drug deposited within the skin was determined. The skin surface was wiped with cotton ball soaked with 50% ethanol. The tape-stripping method (average 10 strips) was used to remove the SC layer. The remaining skin (epidermis/dermis) was weighed, cut into small pieces and homogenized with 0.5 ml of methanol. The extraction solution was then
centrifuged for 10 min. The supernatant was combined and filtered for HPLC analysis.

2.5. Optimization studies

A faced centered cubic Central-Composite design for 3^2 level was selected to optimize response variables by constructing second order polynomial models and exploring quadratic response surfaces with Design Expert® (version 8.0.7.1, Stat-Ease Inc., Minneapolis, Minnesota). Mathematical modeling was carried out by the polynomial equation as follows [12]:

\[ Y = b_0 + b_1X_1 + b_2X_2 + b_3X_1X_2 + b_4X_1^2 + b_5X_2^2 \]

(1)

where Y is the dependent variable associated with each factor level combination; \( b_0 \) is constant; \( b_1, b_2 \) represent linear coefficients, \( b_3 \) is interaction coefficient between the two factors, \( b_4, b_5 \) are quadratic regression coefficients calculated from the observed experimental values of Y from experimental runs; the terms \( X_1X_2 \) and \( X_1^2, X_2^2 \) indicates the interaction and quadratic terms, respectively [13].

The selected independent variables were the EtOH:DGME ratio (\( X_1 \)) and EtOH concentration (\( X_2 \)). The dependent variables were flux (\( Y_1 \)) and skin retention (\( Y_2 \)). The independent and dependent variable with coded levels, low (-1), medium (0) and high (+1) levels were listed in Table 1. Table 4 summarized an account of the 13 experimental runs studies. Two-dimensional contour plots and three-dimensional response surface plots were also developed.

2.6. In vivo studies

2.6.1. In vivo skin permeation study

The back hair of each Wistar rat (200 g) was removed under anesthesia. The test formulations (20 mg/kg) of were applied to a circular test area. The application sites (1.77 cm²) were protected by placing a self-adhering foam pad (Reston™, 3M) supported a teflon ring chamber around the back surface. Blood samples were drawn at 0.17, 0.5, 1, 2, 4, 6, 8, 10, 12 and 24 h via retinal venous plexus. The applied skin of each rat was excised after sacrifice by cervical dislocation at the end of the experiments (24 h). Skin samples were treated same as in vitro study.

2.6.2. Pharmacokinetic study

The blood samples were immediately centrifuged at 10,000 rpm for 10 min, and the plasma was separated and stored at –20 °C until HPLC analysis. Analysis of pharmacokinetic data was carried out using a non-compartmental method. Pharmacokinetic parameters \( C_{\text{max}}, T_{\text{max}}, \text{mean residence time (MRT)}, \text{half-life time (T1/2)}, \text{AUC}_0-24h, \text{and AUMC} \) were derived directly from KINETICA 4.4 (Thermo Scientific, USA).

To develop in vitro-in vivo correlation, the cumulative amount of Lop permeated across hairless mouse skin in vitro was compared against the absorption and cumulative AUC values in vivo.

2.7. Confocal laser scanning microscopy (CLSM) study

For CLSM study, skin samples were obtained by mechanical vertical-section at 10 μm thickness. The analysis was carried out using a Leica TCS SP5 (Leica, Germany) laser scanning confocal microscopy operating at excited wavelength of 543 nm and emission wavelength of 560 nm for Rhodamine 6G (Rh6G) probe.

2.8. Statistical analysis data presentation

All of the results were statistically analyzed by Excel software. Paired two-tailed Student’s t-test was conducted to calculate the statistical significance and \( P < 0.05 \) was considered to be statistically significant. Data were expressed as mean ± the standard deviation.

In this paper, the penetration parameters were explained as below:

- **Flux**: rate of steady-state penetration (diffusion process) (μg/cm²/h)
- **Ps**: coefficient of penetration process (cm/h)
- **Tlag**: the lag time of percutaneous penetration of drugs (The intercept on the horizontal axis)
- **Q24h**: cumulative percutaneous penetration of drugs (skin deeper layer and blood /receptor medium) per unit area(μg/cm).

Modifier ratio (MR) for flux, lag-time and concentration of skin retention were calculated by using the following formula:

\[
\text{MR}_{\text{flux}} = \frac{\text{Flux for formulation containing DGME}}{\text{Flux for control formulation}}
\]

(2)

\[
\text{MR}_{\text{lag}} = \frac{\text{Lag-time for formulation containing DGME}}{\text{Lag-time for control formulation}}
\]

(3)

\[
\text{MR}_{\text{c}} = \frac{\text{Concentration of skin retention for formulation containing DGME}}{\text{Concentration of skin retention for control formulation}}
\]

(4)
3. Results and discussion

3.1. Preliminary study of Lop formulation

The preliminary study of Lop formulation was carried out using test formulations Fc and F0 (Table 2). The patent formulation Fc (NMP solvent system) was regarded as control formulation, while F0 was formulation containing vehicle DGME instead of NMP without changing other compositions. The penetration parameters of flux, Ps, Q, and Tlag (lag-time) were reported in Table 3. Flux of Fc (21.20 ± 6.12 μg/cm²/h) suggested no clear difference with control formulation (26.11 ± 3.29 μg/cm²/h) (P > 0.05, MRflux = 0.81). However, the lag-time for Fc (3.04 ± 1.00h) was significantly lower than F0 (P < 0.01, MR = 0.50), which revealed Lop in Fc was more rapidly accumulated in the skin tissue. Meanwhile, Lop retained in skin of Fc (5.69 ± 0.79 mg/g) significantly increased compared to F0 (4.06 ± 0.45 mg/g), which suggested Lop in F0 obtained a higher skin retention concentration (MRc = 1.40).

In general, the results of topical application of F0 and Fc demonstrated when DGME vehicle was employed, reduction of lag-time and almost the same skin permeation flux value were observed. DGME has been reported to increase the skin accumulation of topically applied compounds [9,14,15]. This provides evidence of the significance of DGME in the formation of cutaneous depots of Lop and the ternary cosolvent gel containing DGME (DGME-EtOH-Water) seems to be candidate for a low-toxic and effective vehicle system for topical delivery of Lop.

3.2. Optimization studies

3.2.1. Fitting data to the model

For the 13 run formulations, the flux value and skin retention were taken as dependent variables and results were recorded in Table 4. The flux value and skin retention for the 13 formulations showed a variation from 9.78 ± 1.99 μg/cm²/h to 65.48 ± 1.67 μg/cm²/h and 2.53 ± 0.56 mg/g to 9.86 ± 0.97 mg/g, respectively. Data was subjected to multiple regressions to yield a second-order polynomial equation. Full model of Y1 and Y2 were established by putting values of regression coefficients for the two response variables (Y1 and Y2) respectively in Eq. 1.

For flux,

\[
Y_1 = +17.69 - 24.86X_1 + 2.85X_1 + 0.31X_2X_3 + 22.80X_1^2 - 2.68X_2^2
\]

(5)

For skin retention,

\[
Y_2 = +5.41 - 1.04X_1 - 2.56X_1 - 0.21X_2X_3 + 1.26X_1^2 - 0.16X_2^2
\]

(6)

The significance of each coefficient of Eqs. 5 and 6 was conducted by F-statistics and P-value. The smaller the P-value, the more significant is the corresponding coefficient [16]. Based on this, effect of EtOH:DGME ratio (X1) and EtOH concentration (%v/v) (X2) on flux value and skin retention were found to be significant, while the quadratic term X2 on skin retention and interaction term X1X3 both in flux and skin retention were found to be non-significant. Non-significant terms (P > 0.05) were reduced and multiple regression was carried out between the significant terms for reduced model (Eq. 7 and Eq. 8).

| Table 2 – Formulations containing Lop. |
|---------------------------------------|
| Formulations | Vehicles | Ratio (v/v/v) | Lop | Klucel®MF (HPMC) |
|---------------|----------|---------------|-----|-----------------|
| Fc            | ETOH-NMP-Water | 4:1:3 | 5% | 0.75% |
| F0            | EtOH-DGME-Water | 4:1:3 | 5% | 0.75% |

| Table 3 – Results of in vitro permeation study of Lop (Preliminary study). |
|------------------|------------------|------------------|------------------|------------------|
| Parameter        | Fc               | F0               | Flux (μg/cm²/h)  |
|                  |                  |                 | 26.11 ± 3.29     |
|                  |                  |                 | 21.20 ± 6.12     |
| Qabs (μg/cm²)    | 492.01 ± 28.77   | 409.42 ± 35.76   |
| Ps × 10⁻⁴ (cm/h) | 5.21 ± 2.26      | 4.48 ± 1.03      |
| Tlag (h)         | 6.03 ± 0.13      | 3.04 ± 1.00      |
| Ps (mg/g)        | 4.06 ± 0.45      | 5.69 ± 0.79      |
| MRflux           | 0.81             | 0.50             |
| MRc              | 0.15             | 1.40             |

Data are means ± SD, n = 6, *P < 0.01 and **P < 0.05 compared with control.
MR, modifier ratio.

Table 4 – Layout of 3² factorial design showing the values of dependent variables of 13 formulations.

| Formulation code | Independent variables | Response variables |
|------------------|-----------------------|--------------------|
|                  | X₁ (EtOH:DGME ratio) | Y₁ (μg/cm²/h) | Y₂ (mg/g) |
| F1               | –1                    | 60.01 ± 3.43      | 9.86 ± 0.97 |
| F2               | –1                    | 65.25 ± 0.98      | 8.01 ± 0.23 |
| F3               | –1                    | 65.48 ± 1.67      | 4.96 ± 1.05 |
| F4               | 0                     | 12.22 ± 2.23      | 7.83 ± 1.14 |
| F5               | 0                     | 17.64 ± 1.59      | 5.21 ± 0.07 |
| F6               | 0                     | 17.14 ± 2.45      | 3.12 ± 0.16 |
| F7               | 0                     | 9.78 ± 1.99       | 8.25 ± 1.15 |
| F8               | 0                     | 15.15 ± 5.23      | 5.79 ± 0.98 |
| F9               | 0                     | 16.57 ± 4.05      | 2.53 ± 0.56 |
| F10              | 0                     | 17.98 ± 1.23      | 5.36 ± 0.24 |
| F11              | 0                     | 17.87 ± 0.89      | 5.43 ± 1.49 |
| F12              | 0                     | 17.78 ± 2.01      | 5.31 ± 0.67 |
| F13              | 0                     | 17.72 ± 1.53      | 5.28 ± 1.86 |

X₁: EtOH:DGME ratio; X₂: EtOH Concentration (%v/v) Y₁: flux (μg/cm²/h); Y₂: skin retention (mg/g).
* Indicates the center point of the design.
Table 5 – Summary of results of regression analysis for response Y1 and Y2 for fitting to reduced quadratic model.

| Quadratic model | R²    | Adjusted R² | Predicted R² | SD     | %CV  |
|-----------------|-------|-------------|--------------|--------|------|
| Response (Y1)   | 0.9997| 0.9995      | 0.9988       | 0.4420 | 1.639|
| Response (Y1)   | 0.9863| 0.9818      | 0.9592       | 0.2784 | 4.704|

Regression equation of the fitted quadratic model:

\[ Y_1 = +17.67 - 24.86X_1 + 2.85X_2 + 22.84X_1^2 - 2.68X_2^2 \]  
\[ Y_2 = +5.36 - 1.04X_1 - 2.56X_1 + 1.20X_1^2 \]  

*a Only the terms with statistical significance are included.

For flux,

\[ Y_1 = +17.67 - 24.86X_1 + 2.85X_2 + 22.84X_1^2 - 2.68X_2^2 \]  

For skin retention,

\[ Y_2 = +5.36 - 1.04X_1 - 2.56X_1 + 1.20X_1^2 \]

The goodness of fit of the model was checked by the determination coefficient and calculated % error value (% CV) indicates the correlation between observed values and predicted values (R², SD, and %CV are given in Table 5). Since the values of R² were quite high for all the two responses, i.e. 0.9997 and 0.9863 (P < 0.001), the generated polynomial equations excellently fits to the experimental data. The values of adjusted determination coefficients (Adj. R² = 0.9995 for flux and Adj. R² = 0.9818 for skin retention) were also high, which indicated a high significance of the reduced model. The predicted R² of Y1 and Y2 were in reasonable agreement with the adjusted R² of Y1 and Y2, which proved that the derived reduced polynomial equation could be useful in prediction.

3.2.2. Effect on flux: response Y1

Skin permeation flux is a very important criterion for Lop topical formulation. The lowest flux was found for F7 (9.78 ± 1.99 μg/cm²/h), and maximum flux (65.25 ± 2.98 μg/cm²/h) was found for F3, respectively. The following polynomial equation was generated for flux of Lop:

\[ Y_1 = +17.67 - 24.86X_1 + 2.85X_2 + 22.84X_1^2 - 2.68X_2^2 \]  

A positive value in regression equation for a response represents an effect that benefit the optimization (synergistic effect), whereas a negative value suggests an inverse relationship (antagonistic effect) between the factor and the response [17]. From the equation, it is evident that the independent variables X1 have a negative effect on the response Y1 (flux) whereas X2 has a positive effect.

Fig. 1A portrayed 2D contour plot systematically showing effect of X1 and X2 on flux. From the contour plot, it was found that Y1 showed a low value (below 10 μg/cm²/h) in the area of 0.094 < X1 < 1, -1 < X2 < -0.391, while the flux above 60 μg/cm²/h could be achieved with X1 ranging from -1 to -0.922.

As seen in Fig. 1B, it was observed that at fixed levels of X1, flux of Lop first decreased with increase of X1 from -1 to 0.534 and further increased with X1 varying from 0.534 to 1. These results clearly indicated the X1 was the major factor in determining flux value and this result thereby confirmed the significant role played by X1 in the skin penetration behavior.

The effect of this factor might be attributed to the interaction of EtOH-DGME vehicle mixture with skin tissue. The EtOH-DGME vehicle mixtures interacted with SC by altering the structure of lipophilic or keratinized domains in SC which caused a SC lipid fluidization and consequently reduced the penetration barrier properties of skin by disrupting the tightly packed lipid structure of the SC. It is worth noting that the effect of penetrating DGME itself across and into the skin should be considered especially. Some authors have confirmed that DGME itself can pass through the dense lipophilic matrix of SC and penetrate into skin [7].

3.2.3. Effect on skin retention: response Y2

When optimizing topical drug delivery, emphasis should be placed on drug concentration in the target tissues. Therefore, skin retention concentration is another important criterion for optimization of topical delivery system for Lop. F1 and F9 presented the highest (9.86 ± 0.97 mg/g) and lowest (2.53 ± 0.56 mg/g) skin retention value, respectively. The developed contour (Fig. 1C) was found to be non-linear with upward and downward trends, indicating non-linear relationship between X1 and X2.

The response Y2, relating to skin retention was revealed by the equation \[ Y_2 = +5.36 - 1.04X_1 - 2.56X_1 + 1.20X_1^2 \]. As revealed by the equation, when the independent variable X1 was fixed, there existed a direct negative effect between EtOH concentration and skin retention. In the 3D-response surface plot showing effect of two independent variables on skin retention, it was also observed that skin retention of Lop decreased with increase in concentration of EtOH (Fig. 1D). This trend of variation of skin retention with varying EtOH concentration was significantly observed in this study, which indicated skin retention of Lop were sensitive to the concentration of EtOH. It suggested that, in this case, X1 showed a dominant effect in skin retention of Lop.

3.2.4. Optimization

The optimum topical formulation of Lop was selected based on the criteria of attaining the maximum value of skin retention and flux by applying point prediction method of the Design Expert software® [18] and total desirability was calculated. The desirability lies between 0 and 1 and it represents the closeness of a response to its ideal value. The selected optimum formulation, with coded values for EtOH:DGME ratio (X1) and EtOH concentration (X2) as -1 and -0.935, respectively. The calculated desirability factor for offered formulation was 0.948, indicating suitability of the designed factorial model. The
optimum formulation (denoted as $F_{op}$) contained EtOH:DGME ratio as 2:1 and EtOH concentration as 35% showed permeation flux of $60.34 \mu g/cm^2/h$ and skin retention of 10.01 mg/g, respectively.

3.3. In vitro studies

3.3.1. In vitro permeation and CLSM study
The selected optimum formulation $F_{op}$ was compared with control ($F_c$) for in vitro skin permeation study (Fig. 2). Significant differences could be found between these two gel formulations with respect to flux and penetration lag-time ($P < 0.01$, $P < 0.05$). Flux for $F_{op}$ gel was promoted to more than 2-fold of $F_c$ gel ($MR_{flux} = 2.31$). Skin retention enhancing effect of $F_{op}$ gel was also observed ($MR_r = 2.47$).

In order to visualize the skin delivery of Fop and Fc, they were made fluorescent by the inclusion of Rhodamine 6G, a red dye ($\log P = 3.4$, Rh6G), which was supposedly to imitate the behavior of Lop ($\log P = 3.1$). As shown in Fig. 2, it was clear that the penetration of $F_c$ was confined to the upper skin layer with less retention in the deeper skin than Fop. While the CLSM images of Fop (with bright fluorescence throughout epidermis/dermis) showed enhanced delivery of active agents as far as the deeper layer of skin and improved skin retention.

3.3.2. In vitro dermatokinetic study
Fig. 2 also showed the distribution of Lop skin retention (epidermis/dermis) of the hairless mice. Delivery of Lop in the skin layers by optimum gel Fop was found to be significantly greater than Fc. Table 6 gives the numeric values of dermatokinetic parameters AUC, $C_{skin\ max}$ and $T_{skin\ max}$. The maximum concentration achieved in skin ($C_{skin\ max}$) for Fop and Fc was $22.44 \pm 3.81 \ mg/g$ and $16.56 \pm 1.88 \ mg/g$, respectively. Moreover, AUC of Lop in skin for Fop was also found to be higher than Fc. The results, therefore, confirmed that Lop in Fop travelling as far as the deeper skin layer and forming deposition within the skin. The main challenge for topical delivery system is to penetrate across through the SC barrier and target the active drug into injury sites as much as possible. Thus, the transport characteristics of Fop showed the expected results.
Fig. 2 – The amount of drug present in the skin (epidermis/dermis) of hairless mice at various time points, in vitro permeation profiles and CLSM images of vertical section of skin incubated with corresponding formulations (Fop, Fc) containing the label Rhodamine 6G. Data were presented as mean ± SD (n = 6).
3.4. In vivo studies

3.4.1. In vivo skin permeation study

After 24 h of in vivo application experiment, the amount of lopretained in the epidermis/dermis of rat skin was determined by HPLC to evaluate in vivo skin retention. Fc delivered only 6.78% of applied Lop dose to deeper layer, whereas Fop delivered a significantly higher (P < 0.05) skin retention to deeper layer (epidermis/dermis) compared to Fc, i.e. it provided 13.12% of the initial dose. The DGME containing formulation Fop showing superior efficacy in in vitro skin permeation study, displayed the same tendency in in vivo study. Such a result was in agreement with in vitro studies.

3.4.2. Pharmacokinetic study

The mean plasma concentration-time curve of Lop after topical application of Fop and Fc was presented in Fig. 3A. Pharmacokinetic parameters were fitted by non-compartment analysis model. AUC-time of Lop was displayed in Fig. 3B and the pharmacokinetic parameters were also shown in Table 7. MRT of Fop (24.10 ± 0.12 h) was much longer than Fc (10.42 ± 2.69 h), which strongly verified drug retained in vivo for longer time. Though exhibited sustained release behavior, Fc approached the maximum concentration within 4 h, which was shorter than Fop (Tmax = 6.0 h). Hence, pharmacokinetic results demonstrated that Fop significantly improve the sustained release of Lop in vivo.

Furthermore, Fop provided much lower AUC0-24h value (974.23 ± 81.12 h ng/ml) than Fc (1751.39 ± 198.55 h ng/ml). The results revealed, for Fop, small amount of drug accessed into blood circulation. For topical drug delivery, enhancing retention of the applied active ingredients in the skin layer with fewer amounts into blood circulation leads to low potential systemic side and toxic effects.

3.4.3. In vitro-in vivo correlation

In vitro-in vivo correlation between the cumulative amounts of drug permeated across hairless mice in vitro and AUC plasma at the same time point showed triphasic curve pattern (Fig. 4). It can be distinguished into three stages for both Fc and Fop. Correlation coefficient R2 values during the three phases were all observed to be over 0.970, which indicated good linear correlation. This point to point correlation of in vitro permeation to in vivo performance followed type A correlation [19]. This excellent in vitro-in vivo relationship demonstrated that in vitro experiments of Lop can be used to screen formulations and predict preclinical and clinical pharmacokinetics in further studies.

4. Conclusions

In summary, the optimum formulation was evaluated by in vitro permeation study, dermatokinetic analysis and in vivo pharmacokinetic study. Good in vitro-in vivo correlation was obtained. Both in vitro and in vivo studies showed consistent results that Fop can achieve sufficient delivery across skin, enhance intra-cutaneous depot and decrease the risk of side effect.

---

Table 6 – Dermatokinetic parameters of Lop topical formulations in epidermis and dermis retention in hairless mice skin (n = 3).

| Dermatokinetic parameters | Fc | Fop |
|---------------------------|----|-----|
| AUC (h mg/g)              | 119.54 ± 25.00 | 205.89 ± 18.96 |
| Cskin max (mg/g)          | 16.56 ± 1.88   | 22.44 ± 3.81   |
| Tskin max (h)            | 8.00 ± 1.50    | 8.00 ± 1.12    |

Table 7 – Pharmacokinetic parameters of Lop after topical application of Fc and Fop in rats (n = 3).

| Parameters       | Fc                     | Fop                     |
|------------------|------------------------|-------------------------|
| AUC0,24h (h ng/ml) | 1751.39 ± 198.55       | 974.23 ± 81.12          |
| AUMC (h2 ng/ml)  | 13234.60 ± 222.76      | 7412.09 ± 675.03        |
| Cmax (ng/ml)     | 207.19 ± 43.10         | 141.11 ± 13.65          |
| Tmax (h)         | 4.00 ± 0.16            | 6.00 ± 0.45             |
| MRT (h)          | 10.42 ± 2.69           | 24.10 ± 0.12            |
| T 1/2 (h)        | 6.35 ± 0.33            | 24.13 ± 3.64            |

Fig. 3 – (A) Plasma concentration-time profiles of Lop after topical application of Fop and Fc. (B) AUC-time profiles of Lop after topical application of Fop and Fc. Data were presented as mean ± SD (n = 3).
Fig. 4 – In vitro–in vivo correlation for Fop (A) and Fc (B) of cumulative amount permeated in vitro versus plasma AUC in rats (n = 3).
Declaration of conflict interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

REFERENCES

[1] Dehaven-hudkins DL, Cortes Burgos L, Cassel JA, Daubert JD, DeHaven RN, Mansson E, et al. Loperamide (ADL 2–1294), an opioid antihyperalgesic agent with peripheral selectivity. J Pharmacol Exp Ther 1999;289:494–502.

[2] Lavrijsen K, Dyck DV, van Houdt J, Hendrickx J, Monbaliu J, Woestenborghs R, et al. Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans. Drug Metab Dispos 1995;23:354–62.

[3] Wuster M, Herz A. Opiate agonist action of antidiarrheal agents in vitro and in vivo-findings in support for selective action. Naunyn Schmiedebergs Arch Pharmacol 1978;301:187–94.

[4] Chen Y, Quan P, Liu X, Wang M, Fang L. Novel chemical permeation enhancers for transdermal drug delivery. Asian J Pharm Sci 2014;9:51–64.

[5] Trottet L, Merly C, Mirza M, Hadgraft J, Davis AF. Effect of finite doses of propylene glycol on enhancement of in vitro percutaneous permeation of loperamide hydrochloride. Int J Pharm 2004;274:213–9.

[6] Jungbauer FH, Coenraads PJ, Kardaun SH. Toxic hygroscopic contact reaction to N-methyl-2-pyrrolidone. Contact Dermatitis 2001;45:303–4.

[7] Ganem-Quintanar A, Lalforque C, Falson-Rieg F, Buri P. Evaluation of the transepidermal permeation of diethyleneglycol monoethyl ether and skin water loss. Int J Pharm 1997;147:165–72.

[8] Mura P, Fauci MT, Bramanti G, Corti P. Evaluation of transcutol as a clonazepam transdermal permeation enhancer from hydrophilic gel formulations. Eur J Pharm Biopharm 2000;9:365–72.

[9] Ritschel WA, Panchagnula R, Stemmer K, Ashraf M. Development of an intracutaneous depot for drugs. Binding, drug accumulation and retention studies, and mechanism of depot. Skin Pharmacol 1991;4:235–45.

[10] Ritschel WA, Hussain AS. In vitro skin penetration of griseofulvin in rat and human skin from an ointment dosage form. Arzneimittelforschung 1988;38:1630–2.

[11] Malakar J, Sen SO, Nayak AK, Sen KK. Formulation, optimization and evaluation of transferosomal gel for transdermal insulin delivery. Saudi Pharm J 2012;20:355–63.

[12] Subramanian N, Yajnik A, Murthy RS. Artificial neural network as an alternative to multiple regression analysis in optimizing formulation parameters of cytarabine liposome. AAPS PharmSciTech 2004;5:E4.

[13] Khajeh M. Application of Box-Behnken design in the optimization of a manetic nanoparticle procedure for zinc determination in analytical samples by inductively coupled plasma optical emission spectrometry. J Hazard Mater 2009;172:385–9.

[14] Yazdanian M, Chen E. The effect of diethylene glycol monoethyl ether as a vehicle for topical delivery of ivermectin. Vet Res Commun 1995;19:309–19.

[15] Godwin DA, Kim NH, Felton LA. Influence of Transcutol on the skin accumulation and transdermal permeation of ultraviolet absorber. Eur J Pharm Biopharm 2002;5:23–7.

[16] Adinayaraya K, Ellaiah P. Response surface optimization of the critical medium components for the production of alkaline protease by a newly isolated Bacillus sp. J Pharm Pharm Sci 2002;5:272–8.

[17] Chopra S, Pathil GV, Motwani SK. Release modulating hydrophilic matrix systems of losartan potassium: optimisation of formulation using statistical experimental design. Eur J Pharm Biopharm 2007;66:73–82.

[18] Gannu R, Palem CR, Yamsani SK, Yamsani VV, Yamsani MR. Enhanced bioavailability of buspirone from reservoir-based transdermal therapeutic system, optimization of formulation employing Box-Behnken statistical design. AAPS PharmSciTech 2010;11:976–85.

[19] Emami J. In vitro-in vivo correlations: from theory to applications. J Pharm Pharm Sci 2006;9:31–51.